Therapies for musculoskeletal disease

Can we treat two birds with one stone?

Christian M. Girgis, Nancy Mokbel, Douglas DiGirolamo

Research output: Contribution to journalArticle

Abstract

Musculoskeletal diseases are highly prevalent with staggering annual health care costs across the globe. The combined wasting of muscle (sarcopenia) and bone (osteoporosis) - both in normal aging and pathologic states - can lead to vastly compounded risk for fracture in patients. Until now, our therapeutic approach to the prevention of such fractures has focused solely on bone, but our increasing understanding of the interconnected biology of muscle and bone has begun to shift our treatment paradigm for musculoskeletal disease. Targeting pathways that centrally regulate both bone and muscle (eg, GH/IGF-1, sex steroids, etc.) and newly emerging pathways that might facilitate communication between these 2 tissues (eg, activin/myostatin) might allow a greater therapeutic benefit and/or previously unanticipated means by which to treat these frail patients and prevent fracture. In this review, we will discuss a number of therapies currently under development that aim to treatmusculoskeletal disease in precisely such a holistic fashion.

Original languageEnglish (US)
Pages (from-to)142-153
Number of pages12
JournalCurrent Osteoporosis Reports
Volume12
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Musculoskeletal Diseases
Bone and Bones
Muscles
Myostatin
Sarcopenia
Activins
Therapeutics
Insulin-Like Growth Factor I
Health Care Costs
Osteoporosis
Steroids
Communication

Keywords

  • Anabolic agents
  • Bone
  • Muscle
  • Osteoporosis
  • Sarcopenia

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Therapies for musculoskeletal disease : Can we treat two birds with one stone? / Girgis, Christian M.; Mokbel, Nancy; DiGirolamo, Douglas.

In: Current Osteoporosis Reports, Vol. 12, No. 2, 2014, p. 142-153.

Research output: Contribution to journalArticle

@article{4b1ce39d3ac24e2a863268183eb6984b,
title = "Therapies for musculoskeletal disease: Can we treat two birds with one stone?",
abstract = "Musculoskeletal diseases are highly prevalent with staggering annual health care costs across the globe. The combined wasting of muscle (sarcopenia) and bone (osteoporosis) - both in normal aging and pathologic states - can lead to vastly compounded risk for fracture in patients. Until now, our therapeutic approach to the prevention of such fractures has focused solely on bone, but our increasing understanding of the interconnected biology of muscle and bone has begun to shift our treatment paradigm for musculoskeletal disease. Targeting pathways that centrally regulate both bone and muscle (eg, GH/IGF-1, sex steroids, etc.) and newly emerging pathways that might facilitate communication between these 2 tissues (eg, activin/myostatin) might allow a greater therapeutic benefit and/or previously unanticipated means by which to treat these frail patients and prevent fracture. In this review, we will discuss a number of therapies currently under development that aim to treatmusculoskeletal disease in precisely such a holistic fashion.",
keywords = "Anabolic agents, Bone, Muscle, Osteoporosis, Sarcopenia",
author = "Girgis, {Christian M.} and Nancy Mokbel and Douglas DiGirolamo",
year = "2014",
doi = "10.1007/s11914-014-0204-5",
language = "English (US)",
volume = "12",
pages = "142--153",
journal = "Current Osteoporosis Reports",
issn = "1544-1873",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Therapies for musculoskeletal disease

T2 - Can we treat two birds with one stone?

AU - Girgis, Christian M.

AU - Mokbel, Nancy

AU - DiGirolamo, Douglas

PY - 2014

Y1 - 2014

N2 - Musculoskeletal diseases are highly prevalent with staggering annual health care costs across the globe. The combined wasting of muscle (sarcopenia) and bone (osteoporosis) - both in normal aging and pathologic states - can lead to vastly compounded risk for fracture in patients. Until now, our therapeutic approach to the prevention of such fractures has focused solely on bone, but our increasing understanding of the interconnected biology of muscle and bone has begun to shift our treatment paradigm for musculoskeletal disease. Targeting pathways that centrally regulate both bone and muscle (eg, GH/IGF-1, sex steroids, etc.) and newly emerging pathways that might facilitate communication between these 2 tissues (eg, activin/myostatin) might allow a greater therapeutic benefit and/or previously unanticipated means by which to treat these frail patients and prevent fracture. In this review, we will discuss a number of therapies currently under development that aim to treatmusculoskeletal disease in precisely such a holistic fashion.

AB - Musculoskeletal diseases are highly prevalent with staggering annual health care costs across the globe. The combined wasting of muscle (sarcopenia) and bone (osteoporosis) - both in normal aging and pathologic states - can lead to vastly compounded risk for fracture in patients. Until now, our therapeutic approach to the prevention of such fractures has focused solely on bone, but our increasing understanding of the interconnected biology of muscle and bone has begun to shift our treatment paradigm for musculoskeletal disease. Targeting pathways that centrally regulate both bone and muscle (eg, GH/IGF-1, sex steroids, etc.) and newly emerging pathways that might facilitate communication between these 2 tissues (eg, activin/myostatin) might allow a greater therapeutic benefit and/or previously unanticipated means by which to treat these frail patients and prevent fracture. In this review, we will discuss a number of therapies currently under development that aim to treatmusculoskeletal disease in precisely such a holistic fashion.

KW - Anabolic agents

KW - Bone

KW - Muscle

KW - Osteoporosis

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=84904207908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904207908&partnerID=8YFLogxK

U2 - 10.1007/s11914-014-0204-5

DO - 10.1007/s11914-014-0204-5

M3 - Article

VL - 12

SP - 142

EP - 153

JO - Current Osteoporosis Reports

JF - Current Osteoporosis Reports

SN - 1544-1873

IS - 2

ER -